Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectral Diagnostics, Toray Medical join forces to tackle sepsis:

This article was originally published in Clinica

Executive Summary

Canadian diagnostics developer Spectral Diagnostics and Toray Medical, a subsidiary of Japan's diversified chemicals group Toray, have formed what they claim to be the first "theranostic" alliance to improve management of severe sepsis. Under the agreement, the two companies will co-promote the use of Spectral's Endotoxin Activity Assay (EAA) for measuring levels of blood-borne endotoxin, together with Toray's Toraymyxin blood purification device for removing the noxious agent. Endotoxin is the most common mediator of sepsis and enables doctors to assess a patient's risk of developing the severe form of the condition.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051972

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel